What is Global Nuclear Drug for Therapeutic Market?
The Global Nuclear Drug for Therapeutic Market is a specialized sector within the pharmaceutical industry that focuses on the development and distribution of nuclear drugs for therapeutic purposes. These drugs, also known as radiopharmaceuticals, are unique in that they contain radioactive substances which can be used to both diagnose and treat a variety of diseases, including cancer. The market for these drugs is global in nature, with demand driven by the increasing prevalence of chronic diseases, advancements in nuclear technology, and the growing recognition of the benefits of targeted therapies. However, the market also faces several challenges, such as the high cost of drug development, stringent regulatory requirements, and the need for specialized facilities and trained personnel to handle radioactive materials. Despite these challenges, the market continues to show strong growth potential, driven by ongoing research and development activities, as well as the increasing availability of nuclear drugs in emerging markets.
Radium-223, Lutetium-177, Iodine-131, Other in the Global Nuclear Drug for Therapeutic Market:
Radium-223, Lutetium-177, and Iodine-131 are some of the key nuclear drugs used in the therapeutic market. Radium-223 is a radioactive drug used to treat prostate cancer that has spread to the bones. It works by mimicking calcium and binding to areas of increased bone turnover, delivering a high dose of radiation directly to the bone metastases. Lutetium-177 is another radioactive drug used in targeted radionuclide therapy. It is used to treat neuroendocrine tumors, a rare type of cancer that affects cells that release hormones into the bloodstream. Iodine-131, on the other hand, is used to treat thyroid cancer. It works by destroying thyroid cells, both normal and cancerous, with minimal effects on the rest of the body. Other nuclear drugs used in the therapeutic market include Strontium-89 and Samarium-153, which are used to relieve bone pain in patients with cancer that has spread to the bones.
Thyroid, Bone Metastasis, Lymphoma, Other in the Global Nuclear Drug for Therapeutic Market:
The Global Nuclear Drug for Therapeutic Market finds its applications in various areas such as thyroid, bone metastasis, lymphoma, among others. In the case of thyroid disorders, nuclear drugs like Iodine-131 are used to treat conditions like hyperthyroidism and thyroid cancer. The drug works by destroying the thyroid gland and any other thyroid cells (including cancer cells) that take up iodine, with little effect on the rest of your body. For bone metastasis, drugs like Radium-223 are used. This drug delivers radiation directly to the site of the bone metastasis, thereby killing cancer cells and relieving pain. In the treatment of lymphoma, nuclear drugs are used in combination with chemotherapy to destroy cancer cells. Other applications of nuclear drugs include the treatment of heart disease, where they are used to evaluate heart function, and in neurology, where they are used to investigate abnormalities in the brain.
Global Nuclear Drug for Therapeutic Market Outlook:
The Global Nuclear Drug for Therapeutic Market, which was valued at US$ 1736.5 million in 2022, is expected to reach a value of US$ 2123.5 million by 2029. This represents a compound annual growth rate (CAGR) of 3.4% during the forecast period from 2023 to 2029. This growth can be attributed to several factors, including the increasing prevalence of chronic diseases such as cancer, advancements in nuclear technology, and the growing recognition of the benefits of targeted therapies. However, the market also faces several challenges, such as the high cost of drug development, stringent regulatory requirements, and the need for specialized facilities and trained personnel to handle radioactive materials. Despite these challenges, the market continues to show strong growth potential, driven by ongoing research and development activities, as well as the increasing availability of nuclear drugs in emerging markets.
| Report Metric | Details |
| Report Name | Nuclear Drug for Therapeutic Market |
| Accounted market size in 2022 | US$ 1771 million |
| Forecasted market size in 2029 | US$ 4734 million |
| CAGR | 15.1% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Bayer, Novartis, China Isotope & Radiation, Dongcheng, Q BioMed, Curium Pharmaceuticals, Jubilant Radiopharma, Lantheus, Aurobindo Pharma, International Isotopes, Mundipharma |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
